Clinical Roles of Interleukin-6 and STAT3 in Oral Squamous Cell Carcinoma
- 15 October 2016
- journal article
- research article
- Published by Springer Nature in Pathology and Oncology Research
- Vol. 23 (2) , 425-431
Abstract
The effect inflammation has on cancer prognosis is marked by the presence of cytokines and chemokines. Interleukin-6 (IL-6) is one a multifunctional cytokine that regulates inflammatory responses. We investigated the roles of IL-6 and STAT3 and examined the relationship between IL-6 signaling and clinicopathological factors in patients with oral squamous cell carcinoma (OSCC). We retrospectively examined 116 patients who underwent radical surgery for OSCC. IL-6 and STAT3 expression were detected by immunohistochemistry. IL-6 and STAT3 positivity were detected by IHC, at 78.4 and 80.2 %, respectively. IL-6 expression was significantly associated with pattern of invasion (P = 0.004), vascular invasion (P = 0.003), and pathological nodal status (P = 0.019). Multivariate logistic regression analysis revealed that IL-6 expression was significantly associated with vascular invasion (P = 0.044). Meanwhile, there was no significant association between STAT3 expression and clinicopathological factors and no significant relationship between IL-6 and STAT3 expression. IL-6 expression was significantly associated with 5-year disease-free survival. These results suggest that IL-6 is involved in lymphangiogenesis and recurrence in OSCC.Keywords
This publication has 36 references indexed in Scilit:
- The Global Burden of Cancer 2013JAMA Oncology, 2015
- Review of STAT3 (Signal Transducers and Activators of Transcription) in head and neck cancerOral Oncology, 2015
- Baseline neutrophil-lymphocyte ratio (≥2.8) as a prognostic factor for patients with locally advanced rectal cancer undergoing neoadjuvant chemoradiationRadiation Oncology, 2014
- Refining the role of preoperative C‐reactive protein by neutrophil/lymphocyte ratio in oral cavity squamous cell carcinomaThe Laryngoscope, 2013
- Interleukin-6 signaling pathway in targeted therapy for cancerCancer Treatment Reviews, 2012
- Interleukin-6 as a therapy target in oral squamous carcinomaExpert Opinion on Therapeutic Targets, 2012
- Immunotherapy for Metastatic Solid CancersAdvances in Surgery, 2011
- IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancerCytokine & Growth Factor Reviews, 2011
- STATs in cancer inflammation and immunity: a leading role for STAT3Nature Reviews Cancer, 2009
- Immunohistochemical expression of interleukin‐4, ‐6, ‐8, and ‐12 in inflammatory cells in surrounding invasive front of oral squamous cell carcinomaHead & Neck, 2009